Kikkawa R, Duvillard D, Stauffacher W
Acta Diabetol Lat. 1981 Apr-Jun;18(2):107-14. doi: 10.1007/BF02098995.
The effects of cyprohepatadine (CPH) on plasma levels, of glucose, insulin and glucagon were studied in rats in order to clarify the diabetogenicity of this compound. CPH was given to the rats at a daily dose of 45 mg per kg body weight via gastric intubation for up to 20 days. Glucose intolerance appeared after 5 days of CPH treatment without significant increase in fasting glucose level. Plasma insulin response to glucose loading was depressed in the early phase of the glucose tolerance test in groups treated for 10 and 20 days. In these groups the insulinogenic index was significantly lowered. Pancreatic insulin content decreased rapidly after single dose of CPH. Plasma level and pancreatic content of glucagon were not changed by this compound. These results suggested that chronic treatment with CPH caused glucose intolerance in rats through its direct influence on pancreatic B-cell function.
为阐明赛庚啶(CPH)的致糖尿病性,研究了其对大鼠血浆葡萄糖、胰岛素和胰高血糖素水平的影响。通过胃插管以每日每千克体重45毫克的剂量给大鼠服用CPH,持续20天。CPH治疗5天后出现葡萄糖不耐受,而空腹血糖水平无显著升高。在接受10天和20天治疗的组中,葡萄糖耐量试验早期血浆胰岛素对葡萄糖负荷的反应受到抑制。在这些组中,胰岛素生成指数显著降低。单次服用CPH后胰腺胰岛素含量迅速下降。该化合物未改变血浆胰高血糖素水平和胰腺胰高血糖素含量。这些结果表明,CPH的长期治疗通过直接影响胰腺β细胞功能导致大鼠葡萄糖不耐受。